Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Here's Why

2026-03-28 06:43:11 ET

Pharvaris N.V. ( NASDAQ:PHVS – Get Free Report ) shares saw unusually-high trading volume on Thursday . Approximately 238,431 shares traded hands during mid-day trading, an increase of 57% from the previous session’s volume of 151,703 shares.The stock last traded at $27.0750 and had previously closed at $26.15.

Analysts Set New Price Targets

PHVS has been the topic of a number of research reports. Leerink Partners set a $38.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Guggenheim increased their price objective on shares of Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Morgan Stanley raised their target price on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Bank of America increased their price target on Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, December 4th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.70.

Check Out Our Latest Stock Report on PHVS

Pharvaris Stock Down 0.1%

The firm’s 50-day moving average price is $26.91 and its 200 day moving average price is $25.24. The firm has a market cap of $1.49 billion, a P/E ratio of -8.52 and a beta of -2.78.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently made changes to their positions in PHVS. General Atlantic L.P. boosted its position in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC increased its position in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC increased its position in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after acquiring an additional 350,000 shares during the period. Deerfield Management Company L.P. boosted its position in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares during the period. Finally, Commodore Capital LP boosted its position in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares during the period.

Pharvaris Company Profile

( Get Free Report )

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Read More

• Five stocks we like better than Pharvaris